Alnylam Q3 Losses Up as R&D Costs Increase | GenomeWeb

Alnylam Pharmaceuticals this week reported a rise in its third-quarter losses as spending increased on its research and development efforts and it paid severance associated with a recent restructuring.

For the three-month period ended Sept. 30, Alnylam's net loss climbed to $9.6 million, or $0.23 per share, from $9.2 million, or $0.22 per share, in the same period a year earlier.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.